03.09.2018 MagForce AG  DE000A0HGQF5

DGAP-News: MagForce AG to participate in nine upcoming international conferences in H2 2018


 
DGAP-News: MagForce AG / Key word(s): Conference MagForce AG to participate in nine upcoming international conferences in H2 2018 03.09.2018 / 14:00 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- MagForce AG to participate in nine upcoming international conferences in H2 2018 Berlin, Germany and Nevada, USA, September 3, 2018 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced its participation in nine upcoming scientific and investor conferences in the second half of 2018: * Geman Fall Conference Date: September 3-4, 2018 Location: Frankfurt, Germany Presentation: Christian von Volkmann, CFO of MagForce AG, Tuesday, September 4, 2018 * Goldman Sachs European Medtech and Healthcare Conference Date: September 5-6, 2018 Location: London, UK Presentation: Ben J. Lipps, CEO of MagForce AG, Thursday, September 6, 2018 * Berenberg & Goldman Sachs Seventh German Corporate Conference Date: September 24-26, 2018 Location: Munich, Germany Presentation: Ben J. Lipps, CEO of MagForce AG, Tuesday, September 25, 2018 * 13th Meeting of the European Association of Neuro-Oncology (EANO 2018) Date: October 10-14, 2018 Location: Stockholm, Sweden * 18th European Congress of Neurosurgery (EANS 2018) Date: October 21-25, 2018 Location: Brussels, Belgium Booth: No. 12 Lunch Symposium: "Local Therapies For Malignant Gliomas" Speakers: Prof Dr Walter Stummer, Director of the Department of Neurosurgery at the University Hospital Muenster, Germany; Colin Watts, MD PHD, University of Birmingham, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, Birmingham, Great Britain Date & Time: Golden Hall, Tuesday, October 23, 2018; 1.15-2.15pm CEST * MEDICA 2018 Date: November 12-15, 2018 Location: Düsseldorf, Germany Community booth: Berlin Partner für Wirtschaft und Technologie GmbH No. F 42, hall 15 * 23rd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO) Date: November 15-18, 2018 Location: New Orleans, Louisiana, USA * German Equity Forum 2018 Date: November 26-28, 2018 Location: Frankfurt, Germany Presentation: Ben J. Lipps, CEO of MagForce AG, Tuesday, November 27, 2018 * Prior Capital Market Conference Date: December 4, 2018 Location: Dreieich, Germany Presentation: Barbara von Frankenberg, Vice President Communications & Investor Relations of MagForce AG, Tuesday, December 4, 2018 About MagForce AG and MagForce USA, Inc. MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm(R) therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. NanoTherm(R), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries. For more information, please visit: www.magforce.com. Get to know our Technology: video (You Tube) Disclaimer This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated. Contact: Barbara von Frankenberg Vice President Communications & Investor Relations T +49-30-308380-77 E-Mail: bfrankenberg@magforce.com --------------------------------------------------------------------------- 03.09.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: MagForce AG Max-Planck-Straße 3 12489 Berlin Germany Phone: +49 (0)30 308 380 0 Fax: +49 (0)30 308 380 99 E-mail: info@magforce.com Internet: www.magforce.com ISIN: DE000A0HGQF5 WKN: A0HGQF Indices: Scale 30 Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Stuttgart, Tradegate Exchange End of News DGAP News Service --------------------------------------------------------------------------- 720037 03.09.2018


Die wichtigsten Finanzdaten auf einen Blick
  2012 2013 2014 2015 2016 2017 2018 2019e
Umsatzerlöse1 0,95 5,44 7,63 2,58 0,47 0,72 0,07 1,40
EBITDA1,2 -4,61 -1,48 -0,75 -1,32 -6,55 -6,74 7,43 -6,00
EBITDA-Marge3 -485,26 -27,21 -9,83 -51,16 -1.393,62 -936,11 10.614,29 -428,57
EBIT1,4 -4,89 -1,60 -0,97 -1,88 -7,46 -7,41 6,83 -6,60
EBIT-Marge5 -514,74 -29,41 -12,71 -72,87 -1.587,23 -1.029,17 9.757,14 -471,43
Jahresüberschuss1 -5,72 -1,63 -1,01 -1,55 -7,23 -7,47 4,36 -6,85
Netto-Marge6 -602,11 -29,96 -13,24 -60,08 -1.538,30 -1.037,50 6.228,57 -489,29
Cashflow1,7 -5,47 -6,79 -8,70 -5,13 -6,58 -5,34 -7,11 -6,50
Ergebnis je Aktie8 -0,24 -0,07 -0,04 -0.06 -0,28 -0,28 0,16 -0,22
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2018 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: AIOS

INVESTOR-INFORMATIONEN
©boersengefluester.de
MagForce
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A0HGQF 4,380 Kaufen 121,06
KGV 2020e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 32,63 0,000 -6,56
KBV KCV KUV EV/EBITDA
6,63 - 1.806,93 18,449
Dividende '19 in € Dividende '20e in € Div.-Rendite '19e
in %
Hauptversammlung
0,00 0,00 0,00 08.08.2019
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
31.10.2019 20.06.2019
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-0,52% -6,83% -16,09% -23,16%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu MagForce AG  ISIN: DE000A0HGQF5 können Sie bei DGAP abrufen

Medtech , A0HGQF , MF6 , XETR:MF6